Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

9.180 +0.050 (+0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Is It Too Late to Buy Viatris Stock?
It's not too late if you're looking for dividend income. 
Via The Motley Fool
7 Stocks 'On Sale' This Holiday Season
This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have... 
Via Talk Markets
7 Stocks 'On Sale' This Holiday Season
The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Pharma Stocks That Are Too Cheap to Ignore
Many stocks are ridiculously expensive right now -- but not these three. 
Via The Motley Fool
Unusual Options Activity Insight: Viatris
On Monday, shares of Viatris (NASDAQ:VTRS) saw unusual opt... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Novartis May Have Buyer(s) For Its Sandoz Unit - Report
According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG... 
Via Benzinga
New Alternatives for Branded Biologics
We’ve all heard about generic drugs. They are time-tested and battle-proven medicines that are more affordable than their patented predecessors. Branded drugs consistently... 
Via Benzinga
7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation
These companies either have no exposure to inflation or have strong branding and customer loyalty, enabling them to pass higher costs. 
Via InvestorPlace
3 Things About Viatris That Smart Investors Know
Don't expect it to follow the trajectory of a hot growth stock. 
Via The Motley Fool
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
Johnson & Johnson will split its consumer health unit into a publicly traded company. 
Via Investor's Business Daily
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Could Viatris Stock Help You Retire a Millionaire?
It depends on how much help you're looking for. 
Via The Motley Fool
Topics Retirement
Exposures Pension
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
3 No-Brainer Biotech Stocks to Buy Right Now
Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run. 
Via The Motley Fool
2 Ultra-Cheap Stocks Trading Below Their Book Values
And these stocks also pay relatively high dividends. 
Via The Motley Fool
Why Are Theravance Bio Shares Plummeting Premarket Today?
Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November... 
Via Benzinga
Why Wall Street Thinks This Dirt Cheap Value Stock Could Soar
It's kind of a boring stock. But analysts think that it could deliver not-so-boring growth. 
Via The Motley Fool
Got $5,000? These 2 Dividend Stocks Are Dirt Cheap Buys
And their yields are both over 3%. 
Via The Motley Fool
3 Things About Pfizer That Smart Investors Know
They're all about the future. 
Via The Motley Fool
Theravance Stock Crashes; Can Longer Testing Salvage Its J&J-Partnered Drug?
Theravance said late Monday its ulcerative colitis treatment failed in midstage testing, and the biotech stock plummeted early Tuesday. 
Via Investor's Business Daily
3 Top Biotech Stocks to Buy in August
Each of these companies makes for a great vehicle to play an aging demographic. 
Via The Motley Fool
Analysts Love This Newly Formed Healthcare Company; Should You?
Viatris' steady operating results and cheap valuation are two key reasons for its high one-year price target. 
Via The Motley Fool
Viatris Inc (VTRS) Q2 2021 Earnings Call Transcript
VTRS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
How This Historic FDA Approval Benefits Viatris
Here's what the FDA's approval of Semglee, from Viatris and Biocon, means for the former. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Viatris Stock Gains After FDA Approves Viatris-Biocon Biologics' Insulin Glargine Biosimilar Injection
The FDA cleared Viatris inc (NASDAQ: VTRS) - Biocon Biologics' Semglee insulin glargine-yfgn injection as a biosimilar. Semglee indicates controlling high... 
Via Benzinga
Exposures Product Safety
How To Find Value Stocks July 2021
Identifying fair value in an inflated stock market is really important, because in all markets, whether bull or bear you can always find value. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.